Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
BETAMETHASONE SODIUM PHOSPHATE
RPH Pharmaceuticals AB
H02AB; H02AB01
BETAMETHASONE SODIUM PHOSPHATE
500 microgram(s)
Soluble tablet
Product subject to prescription which may not be renewed (A)
Glucocorticoids; betamethasone
Not marketed
1993-08-13
BETNESOL® 500 MICROGRAM SOLUBLE TABLETS BETAMETHASONE PATIENT INFORMATION LEAFLET • BETNESOL TABLETS IS A STEROID MEDICINE , prescribed for many different conditions, including serious illnesses. • YOU NEED TO TAKE IT REGULARLY to get the maximum benefit. • DON’T STOP TAKING THIS MEDICINE without talking to your doctor – you may need to reduce the dose gradually. • BETNESOL TABLETS CAN CAUSE SIDE EFFECTS IN SOME PEOPLE (read section on side effects below). Some problems such as mood changes (feeling depressed or ‘high’) , or stomach problems can happen straight away. If you feel unwell in any way, keep taking your medicine, but SEE YOUR DOCTOR STRAIGHT AWAY . • SOME SIDE EFFECTS ONLY HAPPEN AFTER WEEKS OR MONTHS . These include weakness of arms and legs, or developing a rounder face (read section on side effects for more information). • IF YOU TAKE IT FOR MORE THAN 3 WEEKS, YOU WILL GET A BLUE ‘STEROID CARD’ : always keep it with you and show it to any doctor or nurse treating you. • KEEP AWAY FROM PEOPLE WHO HAVE CHICKEN POX OR SHINGLES , if you have never had them. They could affect you severely. If you do come into contact with chicken pox or shingles, SEE YOUR DOCTOR STRAIGHT AWAY . NOW READ THE REST OF THIS LEAFLET . It includes other important information on the safe and effective use of this medicine that might be especially important for you. THIS LEAFLET WAS LAST UPDATED JUNE 2009 . If you have any questions about this medicine, ask your doctor or pharmacist. WHAT IS YOUR MEDICINE? Betnesol 500 micrograms Soluble Tablets are round, pink soluble tablets, scored one side and with ‘Betnesol Evans’ engraved on the other. Each tablet contains 500 micrograms (0.5mg) betamethasone as betamethasone sodium phosphate. The tablets also contain sodium hydrogen carbonate (E500), sodium acid citrate, saccharin sodium, povidone, Erythrosine (E127) and sodium benzoate (E211). Betnesol Tablets are supplied in strip packs of 100 tablets. The marketing authorisation holder is RPH Pharmaceutic Read the complete document
Health Products Regulatory Authority 02 February 2022 CRN00CRZ3 Page 1 of 7 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Betnesol 500 microgram Soluble Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 500 micrograms (0.5 mg) betamethasone as betamethasone sodium phosphate. Excipients: contains 20.9mg sodium per tablet For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Soluble Tablet Small, soluble, pink tablet engraved Betnesol Evans on one side and scored on the reverse. The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS A wide variety of diseases may sometimes require corticosteroid therapy. Some of the principal indications are as follows. Bronchial asthma, severe hypersensitivity reactions, anaphylaxis, rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis, mixed connective tissue disease (excluding systemic sclerosis), polyarteritis nodosa; inflammatory skin disorders, including pemphigus vulgaris, bullous pemphigoid and pyoderma gangrenosum; minimal change nephrotic syndrome, acute interstitial nephritis; ulcerative colitis, Crohn’s disease; sarcoidosis; rheumatic carditis; haemolytic anaemia (auto-immune), acute lymphoblastic and chronic lymphocytic leukaemias, malignant lymphoma, multiple myeloma, idiopathic thrombocytopenic purpura; immunosuppression in transplantation. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Betnesol Tablets are best taken dissolved in water, but they can be swallowed whole without difficulty. The lowest dosage that will produce an acceptable result should be used; when it is possible to reduce the dosage, this must be accomplished by stages. During prolonged therapy, dosage may need to be increased temporarily during periods of stress or in exacerbations of illness (see “Special Warnings and Special Precautions for Use”). Adults The dose used will depend upon the disease, its severity, and the clini Read the complete document